WallStreetZenWallStreetZen

NASDAQ: MBX
Mbx Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MBX

Based on 8 analysts offering 12 month price targets for Mbx Biosciences Inc

Min Forecast
$18.00-48.26%
Avg Forecast
$58.50+68.15%
Max Forecast
$88.00+152.95%

Should I buy or sell MBX stock?

Based on 8 analysts offering ratings for Mbx Biosciences Inc.

Strong Buy
Strong Buy
5 analysts 62.5%
Buy
2 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
1 analysts 12.5%
Although MBX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MBX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MBX stock forecasts and price targets.

MBX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-28
lockedlocked$00.00+00.00%2026-01-16Find Out Why
lockedlocked$00.00+00.00%2026-01-07
lockedlocked$00.00+00.00%2025-12-19Find Out Why
lockedlocked$00.00+00.00%2025-12-04
Truist Securities
Top 14%
87
Strong BuyInitiates Coverage On$50.00+43.72%2025-10-15
Mizuho
Top 24%
77
BuyMaintains$56.00+60.97%2025-09-24
Oppenheimer
Top 24%
77
BuyMaintains$80.00+129.95%2025-09-23

1 of 1

Forecast return on equity

Is MBX forecast to generate an efficient return?

Company
-38.17%
Industry
248.75%
Market
236.88%
MBX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MBX forecast to generate an efficient return on assets?

Company
-36.98%
Industry
114.59%
MBX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MBX earnings per share forecast

What is MBX's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$3.02-139.3%
Avg 2 year Forecast
-$3.83-149.93%
Avg 3 year Forecast
-$3.43-144.63%

MBX revenue forecast

What is MBX's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$37.4M

MBX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MBX$34.79$58.50+68.15%Strong Buy
ORKA$32.34$53.56+65.60%Strong Buy
BCRX$7.45$21.86+193.38%Buy
PGEN$4.38$9.00+105.48%Buy
ELVN$26.02N/AN/A
View Top Biotech Stocks

Mbx Biosciences Stock Forecast FAQ

Is Mbx Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: MBX) stock is to Strong Buy MBX stock.

Out of 8 analysts, 5 (62.5%) are recommending MBX as a Strong Buy, 2 (25%) are recommending MBX as a Buy, 0 (0%) are recommending MBX as a Hold, 0 (0%) are recommending MBX as a Sell, and 1 (12.5%) are recommending MBX as a Strong Sell.

If you're new to stock investing, here's how to buy Mbx Biosciences stock.

What is MBX's earnings growth forecast for 2026-2028?

(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 62.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.25%.

Mbx Biosciences's earnings in 2026 is -$80,495,000.On average, 13 Wall Street analysts forecast MBX's earnings for 2026 to be -$135,528,618, with the lowest MBX earnings forecast at -$201,539,492, and the highest MBX earnings forecast at -$97,217,974. On average, 12 Wall Street analysts forecast MBX's earnings for 2027 to be -$172,195,838, with the lowest MBX earnings forecast at -$220,991,170, and the highest MBX earnings forecast at -$129,655,397.

In 2028, MBX is forecast to generate -$153,920,601 in earnings, with the lowest earnings forecast at -$210,780,386 and the highest earnings forecast at -$90,994,515.

What is MBX's revenue growth forecast for 2026-2028?

(NASDAQ: MBX) Mbx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.93%.

Mbx Biosciences's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast MBX's revenue for 2026 to be $0, with the lowest MBX revenue forecast at $0, and the highest MBX revenue forecast at $0. On average, 11 Wall Street analysts forecast MBX's revenue for 2027 to be $0, with the lowest MBX revenue forecast at $0, and the highest MBX revenue forecast at $0.

In 2028, MBX is forecast to generate $1,677,999,026 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $8,203,650,575.

What is MBX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MBX) forecast ROA is -36.98%, which is lower than the forecast US Biotechnology industry average of 114.59%.

What is MBX's Price Target?

According to 8 Wall Street analysts that have issued a 1 year MBX price target, the average MBX price target is $58.50, with the highest MBX stock price forecast at $88.00 and the lowest MBX stock price forecast at $18.00.

On average, Wall Street analysts predict that Mbx Biosciences's share price could reach $58.50 by Jan 28, 2027. The average Mbx Biosciences stock price prediction forecasts a potential upside of 68.15% from the current MBX share price of $34.79.

What is MBX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MBX) Mbx Biosciences's current Earnings Per Share (EPS) is $7.68. On average, analysts forecast that MBX's EPS will be -$3.02 for 2026, with the lowest EPS forecast at -$4.49, and the highest EPS forecast at -$2.17. On average, analysts forecast that MBX's EPS will be -$3.83 for 2027, with the lowest EPS forecast at -$4.92, and the highest EPS forecast at -$2.89. In 2028, MBX's EPS is forecast to hit -$3.43 (min: -$4.69, max: -$2.03).

What is MBX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MBX) forecast ROE is -38.17%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.